Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.2857.

Several research firms recently issued reports on SVRA. Guggenheim lifted their price objective on Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, September 9th. HC Wainwright lifted their price target on Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, September 3rd. JMP Securities boosted their price target on Savara from $8.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 23rd. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Savara in a report on Thursday, October 23rd.

Savara Stock Performance

NASDAQ:SVRA opened at $4.92 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 11.08 and a current ratio of 11.08. The stock has a market capitalization of $1.00 billion, a PE ratio of -9.84 and a beta of 0.45. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $4.94. The company has a fifty day moving average of $3.88 and a two-hundred day moving average of $3.11.

Savara (NASDAQ:SVRA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, research analysts forecast that Savara will post -0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Sivia Capital Partners LLC grew its position in shares of Savara by 9.1% in the second quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock valued at $95,000 after purchasing an additional 3,459 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Savara by 52.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after buying an additional 4,626 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Savara by 17.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock worth $87,000 after acquiring an additional 5,687 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after acquiring an additional 6,449 shares during the period. Finally, Sio Capital Management LLC boosted its position in shares of Savara by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock valued at $1,657,000 after acquiring an additional 7,197 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.